Vytrus BiotechXMAD:VYT +0.57%69 Quick Ratio is 2.68 as of Dec. 2025, which is 33% above its 10-year median of 2.01. GuruFocus rates XMAD:VYT with a GF Score™ of 69/100 and a GF Value™ of €5.54 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,409 Biotechnology companies, Vytrus Biotech ranks worse than 58.55% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Vytrus Biotech's quick ratio for the quarter that ended in Dec. 2025 was 2.68.
Vytrus Biotech has a quick ratio of 2.68. It generally indicates good short-term financial strength.
The historical rank and industry rank for Vytrus Biotech's Quick Ratio or its related term are showing as below:
XMAD:VYT'
s Quick Ratio Range Over the Past 10 Years
Min: 1 Med: 2.01 Max: 2.68
Current: 2.68
During the past 8 years, Vytrus Biotech's highest Quick Ratio was 2.68. The lowest was 1.00. And the median was 2.01.
XMAD:VYT's Quick Ratio is ranked worse than 58.55% of 1409
companies
in the Biotechnology industry
Industry Median: 3.6
vs XMAD:VYT: 2.68
Vytrus Biotech (XMAD:VYT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Vytrus Biotech Quick Ratio Related Terms
Vytrus Biotech Quick Ratio Historical Data
* Premium members only.
The historical data trend for Vytrus Biotech's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:VYT vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Vytrus Biotech's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vytrus Biotech Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vytrus Biotech's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Vytrus Biotech's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Vytrus Biotech's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vytrus Biotech (XMAD:VYT) has a Quick Ratio of 2.68 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vytrus Biotech and its competitors. This is 33% above median its historical median of 2.01. Over the past decade, Vytrus Biotech's Quick Ratio has ranged from 1.00 to 2.68. According to the industry distribution chart, Vytrus Biotech ranks #825 out of 1409 companies in the Biotechnology industry, placing it in the top 58.6%.
Is Vytrus Biotech's Quick Ratio too high?
Vytrus Biotech's current Quick Ratio of 2.68 is 33% above median its 10-year median of 2.01. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 2.68. The Biotechnology industry median Quick Ratio is 3.60. Vytrus Biotech's value of 2.68 is 25.6% below this industry median. Based on the distribution chart, Vytrus Biotech ranks #825 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vytrus Biotech has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vytrus Biotech's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Vytrus Biotech ranks #825 out of 1409 companies for Quick Ratio. This places Vytrus Biotech in the lower half of its industry. The industry median Quick Ratio is 3.60. Vytrus Biotech's value of 2.68 is 25.6% below this benchmark. Historically, Vytrus Biotech's own Quick Ratio has ranged from 1.00 to 2.68 over the past decade. While the company's 10-year median is 2.01 vs. the industry median of 3.60, Vytrus Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vytrus Biotech's current Quick Ratio of 2.68 is 25.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Vytrus Biotech and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vytrus Biotech's current Quick Ratio is 2.68, which is 33% above median its own 10-year median of 2.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vytrus Biotech stock overvalued right now?
Based on GuruFocus' analysis, Vytrus Biotech (XMAD:VYT) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.54, compared to a current price of €17.50 — trading 215.9% above its estimated fair value. The current Quick Ratio is 2.68, which is 33% above median its 10-year median of 2.01 and 25.6% below the Biotechnology industry median of 3.60. Vytrus Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Vytrus Biotech (XMAD:VYT), the current Quick Ratio is 2.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vytrus Biotech (XMAD:VYT) Overvalued in 2026?
Based on GuruFocus' analysis, Vytrus Biotech stock appears to be overvalued.
The current stock price of €17.50 is trading 215.9% above its estimated GF Value™ of €5.54.
GuruFocus considers Vytrus Biotech to be Significantly Overvalued.
Key valuation signals for XMAD:VYT:
Quick Ratio: 2.68 (33% above median its 10-year median of 2.01)
GF Value™: €5.54 vs. price of €17.50 (215.9% above fair value)
Industry Position: 25.6% below the Biotechnology median (#825 of 1409)
No single metric tells the full story. See the XMAD:VYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vytrus Biotech SA develops natural active ingredients on an industrial scale. The natural actives offered by the company include Nectaria Lithops, Olea Vitae, Turmeric zen, Capilia Longa, Qura Noni.
69GF Score
Get the complete analysis for XMAD:VYT
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:VYT has been successfully added to your 
